Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Analysts

Insulet Co. (NASDAQ:PODD) has earned an average rating of “Moderate Buy” from the sixteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $289.06.

PODD has been the subject of a number of research reports. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Piper Sandler upped their price objective on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Citigroup upped their price target on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group increased their price target on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Institutional Trading of Insulet

A number of large investors have recently modified their holdings of PODD. Baillie Gifford & Co. raised its stake in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after purchasing an additional 79,982 shares in the last quarter. Geode Capital Management LLC grew its position in Insulet by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after acquiring an additional 40,566 shares in the last quarter. Norges Bank bought a new position in Insulet in the fourth quarter valued at $248,806,000. Artisan Partners Limited Partnership raised its position in Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock valued at $201,073,000 after purchasing an additional 149,524 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its stake in Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter.

Insulet Stock Up 0.1 %

PODD stock opened at $272.64 on Tuesday. The stock has a market cap of $19.15 billion, a P/E ratio of 47.09, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock’s fifty day simple moving average is $274.20 and its two-hundred day simple moving average is $251.26. Insulet has a 1-year low of $160.19 and a 1-year high of $289.46.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts expect that Insulet will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.